References
- 1. Anderson, K.B., Guest, J.L. & Rimland, D. (2004). Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis. 39(10), 1507-1513. doi: 10.1086/425360
- 2. Alvarez, D., Dieterich, D.T., Brau, N., Moorehead, L., Ball, L. & Sulkowski, M.S. (2006). Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 13(10), 683-689. doi: 10.1111/j.1365-2893.2006.00749.x.
- 3. Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R. & Snydman, D.R. (2001). Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 32(3), 492-497. doi: 10.1086/318501.
- 4. Cohen, M.H., French, A.L., Benning, L., Kovacs, A., Anastos, K., Young, M., Minkoff, H. & Hessol, N.A. (2002). Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 113(2), 91-98.
- 5. Fleischer, R., Boxwell, D. & Sherman, K.E. (2004). Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 38(8), e79-80. doi: 10.1086/383151.
- 6. Graham, C.S., Baden, L.R., Yu, E., Mrus, J.M., Carnie, J., Heeren, T. & Koziel, M.J. (2001). Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 33(4), 562-569. doi: 10.1086/321909.
- 7. Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Di Bisceglie, A.M., Reddy, K.R., Bzowej, N.H., Marcellin, P., Muir, A.J., Ferenci, P., Flisiak, R., George, J., Rizzetto, M., Shouval, D., Sola, R., Terg, R.A., Yoshida, E.M., Adda, N., Bengtsson, L., Sankoh, A.J., Kieffer, T.L., George, S., Kauffman, R.S., Zeuzem, S. & Team, A.S. (2011). Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 364(25), 2405-2416. doi: 10.1056/ NEJMoa1012912
- 8. Laufer, N., Laguno, M., Perez, I., Cifuentes, C., Murillas, J., Vidal, F., Bonet, L., Veloso, S., Gatell, J.M. & Mallolas, J. (2008). Abacavir does not influence the rate of virological response in HIVHCV- coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther. 13(7), 953-957.
- 9. Martin-Carbonero, L., Soriano, V., Valencia, E., Garcia-Samaniego, J., Lopez, M. & Gonzalez- Lahoz, J. (2001). Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 17(16), 1467-1471. doi: 10.1089/08892220152644160.
- 10. Mira, J.A., Lopez-Cortes, L.F., Barreiro, P., Tural, C., Torres-Tortosa, M., de Los Santos Gil, I., Martin-Rico, P., Rios-Villegas, M.J., Hernandez-Burruezo, J.J., Merino, D., Lopez- Ruz, M.A., Rivero, A., Munoz, L., Gonzalez- Serrano, M., Collado, A., Macias, J., Viciana, P., Soriano, V. & Pineda, J.A. (2008). Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother. 62(6), 1365-1373. doi: 10.1093/jac/ dkn420
- 11. Poordad, F., McCone, J., Jr., Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S., Jacobson, I.M., Reddy, K.R., Goodman, Z.D., Boparai, N., DiNubile, M.J., Sniukiene, V., Brass, C.A., Albrecht, J.K., Bronowicki, J.P. & Investigators, S.-. (2011). Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 364(13), 1195-1206. doi: 10.1056/NEJMoa1010494.
- 12. Rodriguez-Torres, M., Slim, J., Bhatti, L., Sterling, R., Sulkowski, M., Hassanein, T., Serrao, R., Sola, R., Bertasso, A., Passe & Stancic, S. (2012). Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials. 13(3), 142-152. doi: 10.1310/hct1303-142.
- 13. Serrano-Villar, S., Quereda, C., Moreno, A., Perez-Elias, M.J., Casado, J.L., Royuela, A., Dronda, F., Navas, E., Hermida, J.M. & Moreno, S. (2013). Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections. Clin Infect Dis. 57(3), 458-464. doi: 10.1093/cid/cit221
- 14. Tuma, P., Jarrin, I., Del Amo, J., Vispo, E., Medrano, J., Martin-Carbonero, L., Labarga, P., Barreiro, P. & Soriano, V. (2010). Survival of HIV-infected patients with compensated liver cirrhosis. AIDS. 24(5), 745-753. doi: 10.1097/ QAD.0b013e3283366602.
- 15. Vispo, E., Barreiro, P., Pineda, J.A., Mira, J.A., Maida, I., Martin-Carbonero, L., Rodriguez- Novoa, S., Santos, I., Lopez-Cortes, L.F., Merino, D., Rivero, A. & Soriano, V. (2008). Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 13(3), 429-437.